Information Provided By: 
Fly News Breaks for October 15, 2018
BCRX, KALV
Oct 15, 2018 | 06:22 EDT
Stifel analyst Paul Matteis started KalVista Pharmaceuticals (KALV) with a Buy rating and $33 price target. The company's lead asset KVD900, an oral plasma kallikrein inhibitor, has a "realistic shot" at being a best-in-class acute therapy for hereditary angioedema, Matteis tells investors in a research note. He thinks clinical results from competitor BioCryst (BCRX) "corroborate the viability of the oral kallikrein inhibitor approach but simultaneously leave room for improvement."
News For KALV;BCRX From the Last 2 Days
There are no results for your query KALV;BCRX
